表紙
市場調查報告書

熱門市場分析:多囊性卵巢症候群 (PCOS)

Market Spotlight: Polycystic Ovary Syndrome (PCOS)

出版商 Datamonitor Healthcare 商品編碼 594586
出版日期 內容資訊 英文 29 Pages
商品交期: 最快1-2個工作天內
價格
熱門市場分析:多囊性卵巢症候群 (PCOS) Market Spotlight: Polycystic Ovary Syndrome (PCOS)
出版日期: 2019年11月29日內容資訊: 英文 29 Pages
簡介

本報告提供多囊性卵巢症候群 (PCOS)的治療藥市場相關分析,提供在疾病概要和患者數的轉變·預測,目前的主要的治療方法及臨床實驗·認證情形,PCOS治療藥市場趨勢預測 (今後10年份),資本交易的動向,現在開發中臨床實驗的進展等調查。

分析的要點

疾病的背景情況

治療方法

  • Clomiphene citrate
  • 促性腺激素
  • 抗糖尿病藥物
  • 芳香酶抑制劑
  • 抗雄激素劑
  • 口服避孕藥

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

授權合約·資產收購交易

母體專利

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各期

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0182769

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 113.2 million (NIH criteria) to 188.7 million (Rotterdam criteria) prevalent cases of polycystic ovary syndrome (PCOS) in females aged 15-49 years worldwide, and expects that number to increase to between 119.5 million (NIH criteria) and 199.1 million (Rotterdam criteria) by

2026. The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor. These drugs are commonly administered via the oral or subcutaneous routes, with one product also being available in an intramuscular formulation.

Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, gonadotropinreleasing hormone receptor, and SGLT. These therapies are administered orally.

The overall likelihood of approval of a Phase I endocrine asset is 11.9%, and the average probability a drug advances from Phase III is 69.7%. Drugs, on average, take 9.3 years from Phase I to approval in the overall endocrine space.

There has been only one licensing agreement involving PCOS drugs during 2014-19. The deal was an exclusive licensing agreement signed in 2016 between Millendo and AstraZeneca for the worldwide development and commercialization rights to MLE4901. The deal value was not disclosed.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PCOS have been in the late phases of development, with approximately 79% of trials in Phase III-IV, and only 21% in Phase II.

The US has the highest number of PCOS clinical trials globally. Germany and the UK lead the major EU markets, while Indonesia and South Korea share the top spot in Asia.

Clinical trial activity in the PCOS space is dominated by completed trials. Merck KGaA has the highest number of completed clinical trials for PCOS, with five trials.

Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

8 TREATMENT

8 Clomiphene citrate

8 Gonadotropins

8 Antidiabetic agents

8 Aromatase inhibitors

8 Anti-androgens

9 Oral contraceptive pills

10 EPIDEMIOLOGY

15 MARKETED DRUGS

17 PIPELINE DRUGS

20 PROBABILITY OF SUCCESS

21 LICENSING AND ASSET ACQUISITION DEALS

22 PARENT PATENTS

23 CLINICAL TRIAL LANDSCAPE

25 Sponsors by status

26 Sponsors by phase

27 BIBLIOGRAPHY

28 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of PCOS (Rotterdam Criteria), 2017-26
  • 14 Figure 2: Trends in prevalent cases of PCOS (NIH Criteria), 2017-26
  • 20 Figure 3: Probability of success in the PCOS pipeline
  • 21 Figure 4: Licensing and asset acquisition deals in PCOS, 2014-19
  • 23 Figure 5: Clinical trials in PCOS
  • 24 Figure 6: Top 10 drugs for clinical trials in PCOS
  • 24 Figure 7: Top 10 companies for clinical trials in PCOS
  • 25 Figure 8: Trial locations in PCOS
  • 26 Figure 9: PCOS trials status
  • 26 Figure 10: PCOS trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of PCOS (Rotterdam Criteria), 2017-26
  • 13 Table 2: Prevalent cases of PCOS (NIH Criteria), 2017-26
  • 16 Table 3: Marketed drugs for PCOS
  • 18 Table 4: Pipeline drugs for PCOS in the US
  • 22 Table 5: Parent patents in polycystic ovary syndrome